A detailed history of Rafferty Asset Management, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 35,077 shares of YMAB stock, worth $390,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,077
Holding current value
$390,757
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$9.95 - $15.39 $349,016 - $539,835
35,077 New
35,077 $460,000
Q3 2022

Nov 14, 2022

BUY
$13.96 - $19.67 $715,142 - $1.01 Million
51,228 Added 101.25%
101,824 $1.47 Million
Q2 2022

Aug 12, 2022

SELL
$8.22 - $15.13 $737,424 - $1.36 Million
-89,711 Reduced 63.94%
50,596 $766,000
Q1 2022

May 13, 2022

BUY
$6.55 - $17.42 $417,438 - $1.11 Million
63,731 Added 83.23%
140,307 $1.67 Million
Q4 2021

Feb 10, 2022

BUY
$15.51 - $29.31 $558,220 - $1.05 Million
35,991 Added 88.68%
76,576 $1.24 Million
Q3 2021

Nov 10, 2021

SELL
$27.47 - $37.31 $140,646 - $191,027
-5,120 Reduced 11.2%
40,585 $1.16 Million
Q2 2021

Aug 10, 2021

SELL
$25.45 - $37.64 $806,179 - $1.19 Million
-31,677 Reduced 40.94%
45,705 $1.55 Million
Q1 2021

May 10, 2021

BUY
$29.16 - $51.96 $2.1 Million - $3.74 Million
71,969 Added 1329.56%
77,382 $2.34 Million
Q4 2020

Feb 10, 2021

SELL
$37.86 - $54.26 $553,475 - $793,226
-14,619 Reduced 72.98%
5,413 $268,000
Q3 2020

Nov 13, 2020

BUY
$35.13 - $43.62 $455,706 - $565,838
12,972 Added 183.74%
20,032 $769,000
Q2 2020

Aug 07, 2020

BUY
$23.66 - $49.53 $167,039 - $349,681
7,060 New
7,060 $305,000
Q1 2020

May 15, 2020

SELL
$14.39 - $35.8 $244,083 - $607,239
-16,962 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$23.81 - $33.78 $403,865 - $572,976
16,962 New
16,962 $530,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.